Investigation for clinical efficacy and safety of ipragliflozin 50mg and 100mg on type 2 diabetes
- Conditions
- Type 2 diabetes
- Registration Number
- JPRN-UMIN000016131
- Lead Sponsor
- Osaka Saiseikai Nakatsu Hospital Division of diabetes and endocrinology
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 600
Not provided
1) Type 1 diabetes, patients with other types of diabetes or pregnancy diabetes 2) History of severe ketoacidosis diabetic coma or profound come within 6 months 3) Severe infection, perioperative or severe trauma 4) Moderate renal insufficiency(male >1.5mg/dL, female>1.3mg/dL) 5) Severe hepatic impairment 6) History of requirement of hospitalization for severe CV event within 6 months other 7) Patients with pregnancy, breast-feeding, childbearing potential or plan of pregnancy 8) Patients with neuropathic bladder or dysuria 9) Patients with treatment of diuretic drug 10) Patients with SGLT2 treatment at start of this study 11) Patients who has an episode of sensitivity of SGLT-2 12) Patients who are not eligible judged by investigator
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Changes of HbA1c at 52weeks treatment after initiation
- Secondary Outcome Measures
Name Time Method